Table 2 The subgroup analysis for OS in patients with PROC

Combination therapeutic agents

Chemotherapy

0.71[0.61, 0.84]

0.000

0%

0.660

PARP inhibitors

0.86[0.50, 1.47]

0.581

-

-

Trial phase

phase II

0.65[0.54, 0.79]

0.000

0%

0.933

phase III

0.85[0.66, 1.09]

0.196

-

-

Region

non-Asia

0.74[0.62, 0.88]

0.001

5.4%

0.376

Asia

0.66[0.47, 0.94]

0.02

0%

0.997

ECOG

0–2

0.72[0.61, 0.85]

0.000

0%

0.539

0–4

0.76[0.52, 1.13]

0.173

0%

0.529

Primary tumor site

OC, FTC, PC

0.73[0.62, 0.86]

0.000

0%

0.492

OC

0.66[0.41,1.07]

0.094

0%

0.935

Publication year

within 5 years

0.66[0.53, 0.81]

0.000

0%

0.880

5 years ago

0.81[0.65, 1.02]

0.075

1.6%

0.313